Market Dashboard
Veegaland Developers Logo

Veegaland Developers

Listed
MainboardBook Building Issue
Issue Price
₹130 to ₹140
Face Value
₹10 Per Equity Share
Issue Size
₹210 Cr.
Listing On
BSENSE
Live

Allotment Available

Check your individual allotment on the official registrar portal.

Check Allotment

Grey Market

₹5
+3.57% Est. Listing Premium
Est. Listing Price₹145
Updated: 17 Sept 2026, 19:26

About Veegaland Developers IPO

Veegaland Developers, founded in 2007, is a real estate development firm that works on residential, commercial, and mixed-use projects. From planning and construction to modern design and timely execution of property developments, Veegaland Developers handles everything.

Financial Health

Period EndedRevenueAssetsPAT
2024₹114.61₹221.01₹7.83
2025₹196.22₹326.65₹20.37
2026₹254.16₹483.81₹26.61

Live Subscriptions

Tracking
Categoryday 1day 2day 3
qib0.48x0.49x19.13x
nii0.42x1.01x19.41x
bnii0.34x0.9x18.59x
snii0.57x1.22x21.06x
retail0.89x1.78x9.95x
Total0.67x1.25x14.6x

Frequently Asked Questions

The public subscription window officially opens on 10 September 2026 and concludes at 5:00 PM IST on 15 September 2026.
As of the latest market information, the GMP is ₹5, indicating a 3.57% estimated listing premium. GMP is an unofficial market indicator and can change rapidly.
Shares are offered at ₹130 to ₹140. Retail investors must bid for at least 107 shares, requiring a block investment of ₹14,980.
The allotment has been detected as available in the MUFG Intime India Pvt. Ltd. system. You can use the official registrar link on this page to check your individual status. Shares are scheduled to debut on the exchanges on 18 September 2026.
The registrar for this IPO is MUFG Intime India Pvt. Ltd..
The issue size for Veegaland Developers is ₹210 Cr..
The current status of the Veegaland Developers IPO is Listed. This status is determined from the issue and listing timeline using Indian Standard Time.
No. GMP is unofficial and can move significantly before listing. The actual listing price may differ from the GMP-based estimate.